Immunomodulators for prevention and treatment of infectious diseases in food-producing animals.

The goal of immunomodulation in food-producing animals is to regulate immunity for the benefit of the animal and production efficiency. Immunomodulators are substances that exert this control and include cytokines, pharmaceuticals, microbial products, nutraceuticals, and traditional medicinal plants. Although treatment and prevention of infectious diseases are the most common reasons to use immunomodulators, other conditions, such as amelioration of stress-induced immunosuppression, maturation of the neonate's developing immune response, and strategies to reduce the metabolic cost of eliciting an immune response also are well suited for immunomodulation. Continued discovery of new immune regulators and increased understanding of immunity in food-producing animals will ensure new opportunities for the use of immunomodulators in food-producing animals.     

毛皮兽养殖发展与疾病防治技术解答

本文是根据近期（2005）应邀赴河北、山东一些毛皮兽养殖比较集中的地区出诊、讲学与考察时,应从业者要求对一些提出的有关发展及技术问题所作的书面解答.其中包括目前我国毛皮兽养殖业现状、存在的问题及发展策略,以及一些长期存在的营养代谢病、主要传染病防治方面的问题（疫苗质量、使用与免疫程序,免疫失败）的解答.     

Achievements and future perspectives of embryo transfer technology in pigs

Commercial embryo transfer (ET) has unprecedented productive and economic implications for the pig sector. However, pig ET has been considered utopian for decades mainly because of the requirements of surgical techniques for embryo collection and embryo deposition into recipients, alongside challenges to preserve embryos. This situation has drastically changed in the last decade since the current technology allows non‐surgical ET and short‐ and long‐term embryo preservation. Here, we provide a brief review of the improvements in porcine ET achieved by our laboratory in the past 20 years. This review includes several aspects of non‐surgical ET technology and different issues affecting ET programmes and embryo preservation systems. The future perspectives of ET technology are also considered. We will refer only to embryos produced in vivo since they are the only type of embryos with possible short‐term use in pig production.     

Therapy and prevention of cryptosporidiosis in animals

Cryptosporidiosis is a common gastro-intestinal illness in animals and man worldwide. The disease is devastating in immune-suppressed individuals but self-limiting in competent hosts. The infectious stages of the organism (oocysts) are shed in the faeces of affected individuals, survive in adverse environmental conditions and spread by direct contact or through contaminants (food, water). Due to the robustness of the oocysts, their tenacity, tiny size, and resistance to common disinfectants, the parasite is difficult to eradicate from contaminated environments. To obtain sufficient control both treatment of infected hosts and inactivation of oocysts are necessary. Several drugs are commonly used to treat cryptosporidiosis in man and very few in animals but none of them are completely effective in terms of both clinical and parasitological response. Only a few chemical agents are able to inactivate oocysts in the environment including water treatment plants but their application has certain limitations. Therefore, control of cryptosporidiosis remains a global challenge in both veterinary and human medicine. Extensive research has been performed on suitable drugs and disinfectants. Thousands of agents have been tested both in vivo and in vitro. Some are excitingly active in vitro but exhibit poor or no response in clinical trials. Currently, no single or combined drug therapy has proven to be completely effective against this disease. This article will focus on therapy and prevention of cryptosporidiosis in animals including perspectives for new drugs.